Type: immunotherapy
Status: Recruiting
Developer: Stanford University School of Medicine
Stanford researchers developed an antigen-specific immune tolerance approach using engineered nanoparticles presenting islet autoantigens conjugated to apoptotic signals. In early clinical data (2025), newly diagnosed T1D patients showed preserved C-peptide secretion at 12 months vs. rapid decline in controls.
Biodegradable nanoparticles co-deliver islet autoantigens (insulin B:9-23, GAD65) with phosphatidylserine (apoptotic signal) to splenic antigen-presenting cells. This mimics natural tolerance induction via apoptotic cell clearance, generating islet-specific regulatory T cells without broad immunosuppression.
Year: 2025-2026